Skip to main content

Retail Clinics

  • Kaléo’s Auvi-Q auto-injector to return to U.S. in 2017

    RICHMOND, Va.  — Kaléo announced Wednesday that it will be reintroducing its Auvi-Q (epinephrine injection) auto-injector in the United States during the first half of 2017. This would bring another option to the epinephrine auto-injector space at a time when access and affordability in the space have seen focus from patients and legislators. 
     

  • Fred’s offering flu vaccines as season kicks off

    MEMPHIS, Tenn. — Highlighting the more than 200,000 people hospitalized as a result of complications from the flu, Fred’s pharmacy announced Tuesday that it will be offering flu vaccines to help patients proactively protect against the flu. 
     
    Fred’s said that its pharmacists would work with patients to figure out which version of the flu vaccine is best for them. The company also noted that flu vaccines are free with most insurance plans, though copays may apply. 
     

  • Teva, IBM expand Watson Health Cloud collaboration

    LAS VEGAS — In a move aimed at addressing the two challenges of discovering new options for treatment and improving chronic disease management, Teva and IBM on Wednesday announced an expansion of their e-health alliance, with both projects running on the IBM Watson Health Cloud. 
     

  • CDC makes available $70 million in supplemental Zika virus funding

    ATLANTA - The Centers for Disease Control and Prevention on Friday announced the availability of about $70 million in supplemental funding to states, cities and territories to support continued efforts to protect Americans from Zika virus.

  • Hisamitsu launches Salonpas gel patch

    FLORHAM PARK, N.J. — Hisamitsu America has launched the new Salonpas Lidocaine 4% Pain Relieving Gel-Patch, the company announced Monday. The patch includes the maximum strength lidocaine available without a prescription and uses a proprietary hydro-gel technology to soothe aggravated nerves, the company said.
     

  • Napo Pharmaceuticals launches Mytesi

    NEW YORK — Napo Pharmaceuticals on Thursday announced the launch of its Mytesi (crofelemer), approved by the Food and Drug Administration as a treatment for non-infectious diarrhea in patients with HIV/AIDS on retroviral therapy. The active ingredient is a plant-based drug extracted from the red bark sap of a tree in the Amazon, for which Napo has set up a sustainable harvesting program. 
     

  • Merck signs value-based contract with Aetna for Januvia, Janumet

    HARTFORD, Conn. — Merck and Aetna have entered into a value-based agreement for Merck’s Type  diabetes medications Januvia (sitagliptin) and Janumet (sitagliptin plus metformin. The contract will see Merck’s rebates for the drugs based partly on their ability to help Aetna’s commercial members with Type 2 diabetes achieve or maintain treatment goals. 
     

  • FDA approves Flublok Quadrivalent flu vaccine

    FDA approves Flublok Quadrivalent flu vaccine
     
    SILVER SPRING, Md. — The Food and Drug Administration has approved Protein Sciences’s Flublok Quadrivalent flu vaccine, the company announced Wednesday. The vaccine protects against four strains of influenza, three of which are found in trivalent Flublok alongside a fourth strain. 
     
X
This ad will auto-close in 10 seconds